IP Library Granted Patent US 8,759,292
Granted Patent B2
US 8,759,292 · App. 13/372,540 · Granted Jun 24, 2014

Long-acting coagulation factors and methods of producing same

Inventors: Udi Eyal Fima (Beer-Sheva, IL); Gili Hart (Shoham, IL)
Assignee: Prolor Biotech, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,292
App. No.
13/372,540
Granted
Jun 24, 2014
Kind
B2
Abstract

Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

Claims (23)

1. A CTP-modified Factor IX (FIX) polypeptide consisting of a FIX polypeptide and three chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said CTP-modified FIX polypeptide, wherein at least one CTP is optionally attached to said FIX polypeptide via a linker.

2. The CTP-modified FIX polypeptide of claim 1 , wherein at least one CTP is encoded by an amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

3. The CTP-modified FIX polypeptide of claim 1 , wherein at least one CTP is glycosylated.

4. The CTP-modified FIX polypeptide of claim 1 , wherein at least one CTP is truncated.

5. The CTP-modified FIX polypeptide of claim 1 , wherein said linker is a peptide bond.

6. A pharmaceutical composition comprising the CTP-modified FIX polypeptide of claim 1 .

7. A method of treating hemophilia B in a subject comprising administering the CTP-modified Factor IX (FIX) polypeptide of claim 1 to a subject.

8. A method of extending the biological half-life of a Factor IX (FIX) polypeptide, comprising the step of attaching three chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said FIX polypeptide, wherein at least one CTP is optionally attached to said FIX polypeptide via a linker, thereby extending the biological half-life of said FIX polypeptide.

9. The method of claim 8 , wherein at least one CTP is encoded by an amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

10. The method of claim 8 , wherein at least one CTP is glycosylated.

11. The method of claim 8 , wherein at least one CTP is truncated.

12. The method of claim 8 , wherein said linker is a peptide bond.

13. A method of producing a CTP-modified Factor IX (FIX) polypeptide, comprising the step of attaching three chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said FIX polypeptide, wherein at least one CTP is optionally attached to said FIX polypeptide via a linker, thereby producing a CTP-modified FIX polypeptide.

14. The method of claim 13 , wherein the sequence of said CTP-modified FIX polypeptide is the sequence set forth in SEQ ID NO: 31.

15. The method of claim 13 , wherein at least one CTP is encoded by an amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

16. The method of claim 13 , wherein at least one CTP is glycosylated.

17. The method of claim 13 , wherein at least one CTP is truncated.

18. The method of claim 13 , wherein said linker is a peptide bond.

19. A method of improving the area under the curve (AUC), reducing the dosing frequency, or reducing the clearance rate of a Factor IX (FIX) polypeptide, comprising the step of attaching three chorionic gonadotrophin carboxy terminal peptides (CTPs) to the carboxy terminus of said FIX polypeptide, wherein at least one CTP is optionally attached to said FIX polypeptide via a linker, thereby improving the area under the curve (AUC), reducing the dosing frequency, or reducing the clearance rate of said FIX polypeptide.

20. The method of claim 19 , wherein at least one CTP is encoded by an amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2.

21. The method of claim 19 , wherein at least one CTP is glycosylated.

22. The method of claim 19 , wherein at least one CTP is truncated.

23. The method of claim 19 , wherein said linker is a peptide bond.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2014
From: PROLOR BIOTECH, LLC
To: OPKO BIOLOGICS LTD.
Reel/Frame 033828/0057 →
MERGER Recorded Mar 25, 2014
From: PROLOR BIOTECH, INC.
To: OPKO-PROLOR, LLC
Reel/Frame 032522/0310 →
CHANGE OF NAME Recorded Mar 25, 2014
From: OPKO-PROLOR, LLC
To: PROLOR BIOTECH, LLC
Reel/Frame 032524/0897 →
CHANGE OF NAME Recorded Feb 11, 2013
From: MODIGENE INC
To: PROLOR BIOTECH INC
Reel/Frame 029786/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2012
From: FIMA, UDI EYAL; HART, GILI
To: MODIGENE INC.
Reel/Frame 028093/0326 →
Continuity (3)
Continuation In Part 12826754 · Jun 30, 2010
Provisional Application 61224366 · Jul 9, 2009
Related Publication 20120208759A1 · Aug 16, 2012